Requests that the FDA declare that the drug products Medroxyprogesterone Acetate Tablets, 1.25 mg and 7.5 mg, are suitable for consideration in an Abbreviated New Drug Application.
🏛 Food and Drug Administration (FDA)FDA-2026-P-0750
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.